Formation Bio launches $600 million fund to buy or license stalled drug candidates

Forbes reports Formation Bio launched a $600 million fund to buy or license potential drugs that have stalled. CEO Ben Liu hopes to use AI to move them through clinical trials faster; the fund has already licensed two candidates. Axios reports Liu says the fund structure will let Formation pursue more drug programs without diluting existing shareholders.